A Safety and Efficacy Trial of a Treat and Extend Protocol Using Ranibizumab With and Without Laser Photocoagulation for Diabetic Macular Edema

NCT01934556 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

150

Enrollment

OTHER

Sponsor class

Conditions

Diabetic Macular Edema

Interventions

DRUG: Ranibizumab 0.3 mg intravitreal injection
DEVICE: Guided Laser Photocoagulation

Sponsor

Palmetto Retina Center, LLC